Medical technology company Intelligent Bio Solutions has announced that Avon Freight Group has selected its Intelligent Fingerprinting Drug Testing Solution.
The non-invasive solution will be used for random drug testing at three Avon sites in the UK.
This partnership supports Avon’s proactive risk management and employee well-being.
Intelligent Bio Solutions develops intelligent, rapid, non-invasive testing solutions. Its Intelligent Fingerprinting Drug Screening System is designed to advance portable testing using fingerprint sweat analysis.
According to the medical technology company, the cost-effective system has the potential for broader applications across various fields. It screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, commonly found in workplaces.
With sample collection in seconds and results in under ten minutes, this technology offers a valuable tool for employers in safety-critical industries, Intelligent Bio Solutions said.
With Avon on board, INBS expands its client base to over 400 accounts across 19 countries.
Avon is introducing in-house drug testing. They aim to replace costly and intrusive random oral swab tests previously carried out by external providers.
By adopting INBS’ rapid, hygienic, and less invasive fingerprint sweat-based drug testing, Avon enhances workplace safety while fostering a positive work culture.
The non-invasive solution tackles challenges in safety-sensitive industries, streamlining drug testing while supporting employee well-being and compliance.
Last month, Princebuild, a construction firm, adopted INBS’ Intelligent Fingerprinting Drug Screening System.
In the same month, the medical technology company unveiled a significant upgrade to its fingerprinting drug screening system.
Avon Freight Group commercial & procurement contracts manager Martin Bullimore said: “We’ve never had an in-house testing solution before, and moving to fingerprint drug testing is a big step forward for us.
“We recognised the need for a more proactive approach to workplace testing and appreciated the non-invasive nature of this solution.
“The system allows us to conduct random testing without disrupting operations or imposing on our employees’ personal lives and reinforces our commitment to a safe, effective, and respectful workplace.”
The company anticipates growth in 2025, following its US Food and Drug Administration (FDA) 510(k) submission in December 2024.
Expanding into the US opens significant opportunities for INBS and its drug testing technology.
With proven success in the UK, INBS aims to establish a strong presence in the US market.
